PGR (progesterone receptor) by Sherbet, Gajanan
Gene Section 
Review 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(11) 389 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
PGR (progesterone receptor) 
Gajanan Sherbet 
School of Electrical and Electronic Engineering, University of Newcastle Upon Tyne, Newcastle Upon 
Tyne UK and the Institute for Molecular Medicine, Huntington Beach CA, USA; 
gajanan.sherbet@ncl.ac.uk; gsherbet@immed.org
Published in Atlas Database: February 2017 
Online updated version : http://AtlasGeneticsOncology.org/Genes/PGRID41700ch11q22.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68995/02-2017-PGRID41700ch11q22.pdf 
DOI: 10.4267/2042/68995
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2017 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
The progesterone receptor gene PGR is located on 
11q22.1. The functional gene has 8 exons and 7 
introns; the transcript is translated into 933 residues. 
The protein occurs as three isoforms viz. PR-A; PR-
B; PR-C and 11 splice variants. PR-A and PR-B are 
structurally similar.  The function of the splice 
variants is unclear, although some variants might be 
translated and others differentially expressed. The 
nuclear receptor PR isoforms are ubiquitously and 
uniformly expressed in target tissues. They may 
show differential expression in neoplasia with 
progressive changes. In the conventional pathway, 
PR undergoes conformational changes upon ligand 
interaction, translocates into the nucleus and binds 
PREs of responsive genes. PR can also function by 
non-genomic mode. It can activate the extra nuclear 
receptors, mPRs and PGRMC1 to influence cell 
proliferation and invasion via non-canonically 
routes. Both genomic and non-genomic modes of 
signaling may determine the relevance and the 
validity of PR in the progression, prognosis and 
management of breast cancer. The PR engages 
several systems, among them are PI3K/Akt/ MAPK 
and Wnt to influence cell adhesion, proliferation and 
apoptosis. The ER/PR axis is crucial in breast cancer, 
where the physiological outcome would be affected 
by the differential signaling initiated by the 
canonical and the non-canonical receptors. The 
crosstalk between the ER/PR axis and the growth 
factor/PI3K/Akt/mTOR system is also highly 
relevant. PGR mutations and polymorphism are 
infrequent in cancers. The polymorphic PROGINS 
has been linked, not indisputably, with cancer risk. 
Many SNPs have been identified, mostly 
inconsequential ones. Some may be related to breast, 
endometrial and colorectal cancer risk.  PR produces 
good clinical outcome in breast cancer 
independently of ER. It displays greater correlation 
than ER with disease progression and prognosis. It 
may be differentially expressed in benign prostatic 
hyperplasia and progressive cancer. The expression 
may reflect androgen-insensitivity. PROGINS is 
said to increase ovarian cancer risk, but, 
paradoxically, reduce breast cancer risk. The use of 
progesterone antagonists or agonists has been 
advocated. PRs can act as activators or repressors of 
transcription, necessitating the identification of the 
functional PR/ER isoforms. Some new progestins, 
employed in HRT, have been claimed to prevent 
certain forms of cancer. 
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Identity 
Other names: PR, NR3C3 
HGNC (Hugo): PGR 
Location : 11q22.1 
Location (base pair) 
Start: 101,029,624 bp end:101,130,524 bp reverse 
strand. 
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Figure 1:  Diagrammatic representation of 11q22.1 with PGR together with local gene sequence. 
CNTN5: Contactin 5; ARHGAP42: RhoGTPase Activating Protein; PGR: Progesterone Receptor; TRCP: Transient Receptor 
Potential Cation Channel Subfamily C Member 6; ANGPTL5: Angiopoietin-like Protein 5; CEP126: Centrosomal Protein 12; 
YAP1: Yes-associated protein 1 of the Hippo signalling system 
 
 
Figure 2:  The figures shows PGR-001 transcript ENST00000325455.9 (not drawn to scale). 
 
DNA/RNA 
Description 
The functional PGR gene has 8 exons and 7 introns. 
The 13,748 bps transcript is translated into 933 
residues The gene has 11 splice variants. It uses 
separate promoters and translational start sites in 
Exon 1 to produce two principal isoforms, PR-A and 
PR-B 
(http://grch37.ensembl.org/Homo_sapiens/Gene/Su
mmary?g=ENSG00000082175;r=11:100900355-
101001255). 
Protein 
Description 
The isoforms PR-A and PR-B are the products of a 
single gene. The top Figure 3 shows the use of  
separate promoters and translational start sites to 
produce the two principle PR isoforms PR-A (94 
kDa) and PR-B (118 kDa). The isoforms contain a 
DNA binding domain and a ligand binding domain. 
N-terminal to the DBD is an AF-1 (activation 
function -1) and in the C-terminal direction a nuclear 
localisation signal and the LBD containing AF-2. 
The PR-B isoform has a 164 aminoacid stretch at the 
N-terminus with an AF-3 (Figure 3c). It is believed 
that AF-1 is thought to mediate ligand-independent 
activity, whilst AF-2 is attributed wih ligand-
dependent PR activation. The N-terminal inhibitory 
subdomain of ?155 amino acids is not shown; The 
inhibitory domain does not function in the PR-B 
isoform.  
AF-1 is about 456-546.  
The third isoform is the splice variant PR-C. PR-C 
can bind the ligand, but in the absence of the DBD 
would not be able to bind to PREs of target genes. 
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Figure 3:  A and B reproduced from Li X, O'Malley B. (2003) by permission from Dr B. O'Malley. berto@bcm.edu. Figure C is 
based on Wardell et al. (2005). The dimensions of the domain are not drawn to scale. 
The domain structure of PR isoforms. DBD: DNA binding domain; LBD: Ligand binding domain; AF-3, AF-1, AF-2: Activation 
domains 
 
Alternatively spliced variants 
Many truncated splice variants of PR are generated 
and these are not easily detected by standard anti-PR 
antibodies (Cork et al. 2012) and often specimens 
may be designated as PR-negative. However, in the 
absence of firm evidence that these are functionally 
relevant in the cancer process, the inability to detect 
them may not be of much consequence. 
Besides the three major isoforms, several splice 
variants of the gene have been identified. These are 
a result of the deletion of some of the eight exons of 
PR or by the retention of intronic sequences (see 
Cork et al. 2008). Two variants were translated into 
protein and were found to be differentially expressed 
in the endometrium (Springwald et al. 2010). 
However, the functional status of the variants is 
unclear. Variants with the deletion of exons 4, 6 and 
4/6 (delta exons), and another one with partly deleted 
exon 6 have been identified. Their expression was 
higher in early/mid proliferative endometrium than 
in the secretory phase (Marshburn et al. 2005).  
This suggests that they might be functionally not 
relevant. For, in the proliferative phase oestrogen 
induces high mitotic activity in the epithelium and 
the stroma.  
The secretory phase is characterised by the action of 
progesterone towards the differentiation of the 
endometrium. 
It ought to be pointed out here that the PR delta 4/6 
showed a slight difference in expression between 
1/45 normal and 5/45 breast cancer tissues of the 
patients (Nagao et al. 2003). Whilst reports of 
deletion variants are many, some earlier work has 
claimed the detection of insertion variants. One such 
is a variant with a 232 bp nucleotide insertion 
sequence between exons 4 and 5 in normal 
endometrium (Yamanaka et al. 2002). However, in 
the absence of information whether the variant 
transcript is translated, the inference of a potential 
relevance in normal or pathological condition of the 
endometrium is not warranted. 
Splice variants: PR-delta4, PR-delta6, PR-delta6/7, 
PR-T, PR-S, PR-M, PR-i45 (insertion variant) i45a 
and i45b. 
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Figure 4:  Figure 4 shows the effects of the canonical and non-canonical oestrogen receptor signalling. The isoforms can act as 
activators or repressors of transcription. PR-A is a ligand dependent repressor of PR-B. The PR-A and PR-B isoforms regulate 
different sets of target genes. The PR-B isoform is associated with increase in cell migration but not on cell proliferation or 
survival. PR-B activates many progesterone response genes by activating Src/MAPK signalling pathways, which can promote or 
inhibit cell proliferation (see also legend below). Progesterone induces endometrial proliferation and angiogenesis via the VEGF 
route. Both mPR and PGRMC1 can directly interact with progesterone and function independently of PR. PGRMC1 is also able 
to induce physiological effects by interaction with EGFR. Some of these pathways are not shown here. PGRMC1 : Progesterone 
receptor membrane component 1. 
 
Expression 
PR is expressed ubiquitously in human tissues as 
homo- or heterodimers. The isoforms are expressed 
in relatively equal abundance in most target tissues. 
In the event of neoplastic transformation, the 
isoforms might be differentially expressed and 
display progressive changes (see Scarpin et al. 
2009). 
Function 
Function and Signalling  
Progesterone signalling generates its physiological 
effects by the conventional canonical nuclear 
receptor (PR) pathway and also by the seven-pass 
membrane receptor (mPR).  
The nuclear receptor PR is a transcription regulator. 
Upon ligand binding the principal isoforms PR-A 
and PR-B homo- or hetero-dimerize and function as 
transcription factors. The binding of ligands, agonist 
or antagonist, initiates a conformational change in 
PR leading to its translocation to the nucleus and 
binding to PRE of the responsive genes. The 
possibility that PR might function via a non-genomic 
mode cannot be excluded. 
The rapidity of some responses to progesterone has 
suggested the presence of extranuclear receptor, 
such as the membrane associated mPRs and 
PGRMC1 (progesterone receptor membrane 
component 1). The mPRs are GPCRs belonging to 
the PAQR (progestin and adipoQ receptor) gene 
family (Tang et al, 2005.  
The mPRs and the PGRMC proteins belonging to a 
different family are encoded by different genes. It 
has been noted that target cells may respond to 
progesterone and produce biological effects via the 
mPRs and the PGRMC1. This would involve the 
engagement and activation of allied signalling 
systems that culminate in the phenotypic outcome. 
The mPRs function like GPCRs and also directly 
interacts with progestrone. The physiological 
outcome can occur independently of PR. PGRMC1 
can directly interact with progesterone even in the 
absence of PR. The present indications are that both 
increase cell proliferation and migration. In fact, 
PGRMC1 may also facilitate cell proliferation and 
tumour growth. A small molecule inhibitor of 
PGRMC1 counteracts these effects. This inhibitor 
also destabilises EGFR expression, which would 
suggest that the PGRMC1 effects are to mediated by 
interaction with EGFR (Ahmed et al. 2010a, b). 
Although cell proliferative signalling does seem to 
be modulated by mPRs and the PGRMC1, there is a 
need to resolve whether mPRs and PGRMC1 work 
in the same phenotypic direction or exert opposing 
effects. Recent developments make it imperative that 
the non-canonical mode of progesterone signalling is 
borne in mind while assessing the validity of PR in 
breast cancer management. The PR-mediated 
response to progesterone involves Wnt signalling, 
PI3K/Akt/ MAPK signalling; the phenotypic 
outcome is on cell adhesion, proliferation and 
apoptosis. The ER/PR signalling axis has assumed 
much significance in the management of breast 
cancer patients. However, interpretation of their 
expression and physiological effects are complicated 
by several factors. The cell proliferation/survival 
results depend upon the ER/PR signalling axis 
subject to the provision of which isoform of ER or 
PR is functional and the recognition that ER does 
influence PR function. ERα and ERβ are two ER 
isoforms. ERα is pro-proliferation whilst ERβ is 
inhibitory of cell proliferation. ERα binds to and 
downregulates PR. The PR-A promoter does contain 
an ERE half site/Sp1 binding site and ER does bind 
directly to this site (Petz and Nardulli. 2000). Three 
functionally different PR isoforms of PR, viz. PR-A, 
PR-B and PR-C have been identified (reviewed by 
Kariagina et al. 2008). High PR-A expression has 
correlated with tumour relapse and with associated 
mutations in the breast cancer susceptibility genes 
BRCA1 andBRCA2 (Hopp eet al. 2004; Mote et 
al.2004). The differential expression of the isoforms 
may be due to methylation (Pathiraja et al. 2011).  
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Figure 5:  Figure 5 shows the routes of PGR signalling and the crosstalk with the ER signalling pathways and transactivation of 
EGFR, Wnt/?-catenin ( CTNNB1) possibly influencing cell proliferation. This figures shows an additional mPR route to cell 
proliferation via PKA/cAMP activating the transcription factors CREB / CREM / ATF-1. The earlier figure has not shown this, but 
has indicated mPR working through the MAPK/Akt and NO route to cell proliferation and invasion. It ought to be noted here that 
the activation of the MAPK/ ERK1 ( MAPK3)/ERK2 ( MAPK1) route leads to cell survival and proliferation. The ASK1 ( 
MAP3K5)/JNK/p38 (signalling is a pro-apoptosis route. There is considerable evidence of crosstalk between the ER/PR axis and 
the growth factor/PI3K/Akt/mTOR system as shown here. This can effectively explain the downregulation of PR. One has to be 
mindful also of the possibility that PR may be expressed as splice variants that may not be detected by the antibodies that are 
currently employed for PR assessment. The PR signalling system may engage in crosstalk with neighbouring genes. The 
YAP/TAZ of the Hippo system is known to target ER/PR. YAP and WBP2 (WW domain binding protein-2) have been shown to 
transactivate ER/PR (Dhananjayan et al. 2006). The YAP and ER/PR may be co-ordinately regulated in breast cancer. However, 
it would be necessary to know whether the changes expression of ER and PR occur of their isoforms uniformly or in a differential 
fashion before any firm conclusions can be drawn concerning how this co-ordination takes place and what the outcome might be. 
 
The PR-A and PR-B isoforms seem to regulate 
different sets of target genes. PR-B isoform is 
associated with increase in cell migration but not on 
cell proliferation or survival. Suppression of PR-B 
inhibits cell migration. Many publications have 
reported contradictory phenotypic effects of PR 
agonists and antagonists. These are most likely the 
outcome of the differential signalling by the 
canonical and the non-canonical receptors, which is 
not often taken into cognisance. The differential 
signalling is highlighted in Figure 5 
The ER/PR signalling axis displays a complex 
circuitry of interaction and inter-regulation. When 
ER is non-functional the hormonal response is 
attenuated. When functional, ER can induce the 
expression of PR. Equally, PR can regulate ER 
function. In breast cancer cells, both oestrogen and 
progesterone can activate the Src/Erk pathway. PR 
possesses two domains that can interact with the 
ligand-binding domain of ERα and in this way 
mediate the activation of Src signalling (Ballaré et al. 
2003). In fact, PR may regulate ER function in breast 
cancer and possibly also negatively regulate other 
oestrogen-activated signalling to suppress cell 
proliferation (Mohammed et al. 2015). Besides 
operating the canonical path of genetic transcription 
by binding to EREs in responsive genes, the ER can 
also function in a non-genomic fashion which does 
not involve direct genetic regulation. ER can 
influence cell proliferation by the activation of 
PI3K/MAPK signalling. Also, the G-protein coupled 
receptor GPCR30 has been recognised as a 
membrane receptor of oestrogen and the activation 
of GPCR30 leads to signalling by the non-genomic 
mode. The oestrogens produce many physiological 
effects by activating of GPCRs and driving 
PI3K/Akt and MAPK/ERK signalling. Oestrogens 
can also upregulate the expression of MMPs and 
promote invasion. Therefore, the overall outcome 
would be a result of the balance of activation of the 
ESR1/PR axis, including the balance of the PR 
isoforms. This probably applies also to the 
promotion or inhibition of inflammatory responses. 
Presumably, this is one of the reasons why so much 
controversy has surrounded the clinical value of PR 
in breast cancer, which is nonetheless shown to be a 
significant factor in patient management (reviewed 
by Sherbet, 2011, 2017). Another caveat to be 
considered is that the ER/PR signalling axis may be 
influenced by neighbouring genes such as the YAP1/ 
TAZ of the Hippo system. 
Mutations 
Somatic 
PGR mutations are infrequent in cancers; the 
frequency is around 1% for all cancers. Mis-sense 
mutations were the most frequent type. The mutation 
frequency for endometrial cancer, adenocarcinoma 
of the stomach, cutaneous melanoma, small cell lung 
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cancer (SCLC), and oesophageal carcinoma was 
between 2.6% to 4.4% of samples with PAMs (point 
accepted mutations). The frequency of all PGR 
mutation for breast cancer was 0.52% and for 
ovarian cancer 0.32 (IntOGen; 
www.intogen.org/search?gene=PGR).  
Among the many polymorphic forms of the PGR 
gene is the polymorphism called PROGINS. This 
has a PV/HS-1 Alu insertion in intron 7 and two 
point mutations, V660L in exon 4 and H770H in 
exon 5. The Alu element has a half ERE/Spl binding 
site, which enhances the transcription function of 
PROGINS in response to oestradiol (Agoulnik et al. 
2004). PROGINS may be associated with enhanced 
risk of ovarian, breast and prostate cancer (Leite et 
al. 2008; Govindan et al. 2007; Engehausen 2005). 
Equally, some studies have denied the link of 
PROGINS with cancer risk.  
Over the past decade several SNPs in the PGR gene 
have been identified; many are inconsequential ones, 
but some have been related to possible links to the 
risk of development of breast, endometrial and 
colorectal cancers and endometriosis. The SNPs 
occur in the exons and some in the promoter region 
of the gene which is thought to have altered the 
expression of the receptor. These findings have not 
enabled substantive conclusions regarding their 
significance to the disease process. The presence of 
SNPs in the ER genes should also be sought whilst 
looking any PGR abnormalities. The perceived 
changes in the expression of PGR transcripts or the 
proteins cannot be assumed to be a direct 
consequence of the SNPs in PGR genes. The latter 
could well be a secondary outcome of alterations in 
ER. 
Implicated in 
Breast cancer 
Prognosis 
ER and PR are invaluable aids in assessing the 
growth and progression of breast cancer. These 
receptors are important prognostic markers. The 
correct functioning of PR seems to be essential for 
proper growth signalling by ER. In historical 
perspective, the significance of PR is highlighted by 
the finding that ER+/PR+ patients have good 
prognosis and may respond better to hormone 
treatment than ER+/PR- patients. Combining ER/PR 
expression with cell proliferation markers is 
predictive of nodal involvement and 5-year disease 
free survival (Osborne, 2005; Andronas et al. 2003). 
Furthermore, ER-/PR+ tumours respond to 
endocrine therapy better than ER-/PR- tumours. 
Possibly, PR may produce good clinical outcome 
independently of ER. Patients with PR+ disease 
show longer survival (Osborne, 1998; Osborne et al. 
2005; Lapidus et al. 1998). A recent report states that 
post-menopausal women are at greater risk of 
developing PR-negative ovarian cancer than a 
corresponding group of pre-menopausal women. 
The use of oral contraceptives or HRT did not have 
any influence (Shafrir et al. 2016). However, this 
study has not differentiated between PR-B and PR-
A expression. This is an important provision. They 
subscribe to the view that the deregulation of ER 
signalling could have led to the loss of PR. ERα can 
totally suppress PR signalling and in the absence of 
ERα, PR-A can inhibit the suppressor effects of PR-
B. It is needless to say that the established view is 
that pre-menopausal women run a higher risk of 
ovarian cancer than post-menopausal women. But 
for this generalisation the corresponding information 
on PR status is not currently available. Also, 
paradoxically, the situation obtaining in breast 
cancer is quite the opposite. The use of aromatase 
inhibitors has no plainly perceived advantage in 
ER+/PR- breast cancer. Whether the findings have 
any beraring on the use of these inhibitors in ovarian 
cancer is debatable. 
Purdie et al. (2014) reported that the breast cancer 
molecular subtype luminal A reflects the best 
prognosis.  Indeed, luminal A consistently shows 
high PR expression than luminal B (Prat et al. 2014). 
Caronongan et al. (2016) have analysed ER/PR data 
derived from both immunohistochemical and ligand 
binding assays, The IHC-determined PR correlated 
more significantly than ER with both nodal status 
and 5-year disease-free survival. Also in ligand 
binding assays, PR correlated better than ER with 
survival. A clear differentiation between PR and ER 
has emerged from this study, with PR displaying 
greater correlation than ER with disease progression 
and prognosis.  
Cytogenetics 
There is very little cytogenetic assessment of the 
association of PR and ER with chromosomal 
abnormalities and the prevalence of homogeneusly 
staining regions. Efforts were made in this regard 
some years ago. Some reports have claimed 
correlations of reduced ER and or PR with 
cytogenetic abnormalities. But no valuable 
information has accrued so far.  
A translocation involving Xq24 of the PGRMC1 
locus has been reported to be associated with 
reduced expression of PGRMC1 (Mansouri et al. 
2006).  
The deletion of 11q21 is not infrequent in 
lymphoproliferative disorders and  non-Hodgkin's 
lymphomas. The known translocations involving 
11q21 do occur at the identified breakpoints 
(Fletcher et al. 1993). Whether these affect 11q22.1 
is not known. The 11q22-q23.1 region itself does 
harbour breakpoints at which translocations and 
deletions occur in hematologicval malignancies 
including AML and non-Hodgkins lymphoma 
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(Tanaka et al.2001). Interestingly, a breakpoint has 
been established which includes the PGR sequence 
in 11q22.2-q25 (Ben-Abdallah-Bouhjar et al. 2013). 
Ovarian non-Hodgkin's lymphoma can be ER- and 
PR-negative (Johansson et al. (2003), but one should 
hasten to add that there is no suggestion that this is 
due to the loss of or translocation involving the PR 
locus.  
Genetic recombination, whether in the form of 
translocations or sister chromatid recombination, 
tend to occur at fragile sites and these 
recombinations can include growth factor genes and 
genes linked with tumorigenesis. Sister chromatid 
recombination occurs more frequently at the fragile 
sites. Five fragile sites can be identified in the region 
11q13 to q23.3, viz. three common fragile sites 
FRA11F 11q14.2, FRA11G 11q23.3 and FRA11H 
11q13, and two rare folate sensitive fragile site r- 
FRA11A 11q13.3 and r-FRA11B 11q23.3 
(Debacker and Kooy, 2007). 
Prostate cancer 
Prognosis 
High levels of PR have been claimed to correlate 
with prostate cancer progression. Differential 
expression has also been reported in benign prostatic 
hyperplasia and cancer. However, given that ligand 
activated PR-A can inhibit PR-B effects, it is 
essential to note this differentiation and 
appropriately check the status of both isoforms to 
make a valid conclusion.   
A link seems to have been established between PR 
expression levels and androgen-insensitivity of 
prostate cancer. The findings appear to suggest that 
PR could be taking control in the loss of androgen 
mediated regulation (Detchokul et al. 2015). It has 
been suggested this could be due to the similarities 
between the androgen receptor and PR in respect of 
their DNA binding domain sequences. 
Ovarian cancer 
Note 
The expression of genetic variant PR isoforms and 
PROGINS has been attributed with alteration of risk 
of developing ovarian cancer. But, equally, this has 
been strongly disputed. There is no overwhelming 
evidence that the isoforms or the PROGINS 
haplotype expression is associated with 
gynaecological malignancies. Quite paradoxically, 
the PROGINS allele has been attributed with 
enhancing ovarian cancer risk while decreasing 
breast cancer risk. A similar differentiation has also 
been claimed in respect of the risk of developing PR-
negative ovarian cancer in post-menopausal women. 
The status of the BRCA genes could be relevant in 
this context. An illuminating fact that has emerged 
recently is the association of PR polymorphism in 
the presence of PROGINS with ovarian cancer risk 
in a group of patients carrying mutations in the 
BRCA1 cancer susceptibility gene. Three of the 
variants which were associated unfavorably with 
enhanced risk also adversely affected disease-free 
survival (Tecza et al. 2015). It would be interesting 
to see such a link exists in breast cancer which has a 
familial link with ovarian cancer.  
At present there is no evidence of an association in 
cervical neoplasia or uterine fibroids. Mutation at a 
low frequency and some SNPs have been related to 
some gynaecological malignancies and breast cancer 
as stated above. 
To be noted 
Note 
The use of progesterone antagonists or agonists to 
control cell proliferation is not a new thought. The 
effects of agonists such as mifepristone, ORG 31710 
and onapristone as single agents or in combination 
with inhibitors of the interacting ER system were 
investigated some while ago (Klijn et al. 2000). 
However, a most important obstacle to the proper 
assessment the outcomes of many subsequent studies 
is that one has to have accurate information on the 
functional PR and ER isoforms. PRs can act as 
activators or repressors of transcription. PR-A is a 
ligand dependent repressor of PR-B, mPR and ERβ. 
The prevailing molecular environment is a critical 
factor.  
Mifepristone can inhibit cell proliferation, and 
downregulate VEGFA expression and suppress 
angiogenesis (Elmaci et al. 20016). Combination 
with angiogenesis inhibitors would be an open 
option.  
There has been enhanced interest in mifepristone and 
its metabolite metapristone as therapeutic agents, 
given that they can suppress ER and glucocorticoid 
receptor induced cell proliferation. Mifepristone is 
also said to influence E-cadherin expression which 
would suggest possible suppression of invasion. This 
is claimed to be associated with the suppression of 
EMT (Yu et al. 2016). Other adhesion dependent 
modes of action have also been implicated.  
These findings vastly strengthen the case for the 
therapeutic use of the drug.  
In a placebo controlled double blind trial disease free 
progression was noted over a two year period in a 
third of eligible patients with unresectable 
meningioma treated with mifepristone (Ji et al. 
2015). Onaprinstone also inhibits cell proliferation. 
However, its hepatotoxicity might have muted the 
interest in it.  
Many clinical trials assessing the effects of 
mifepristone are underway; the outcome is awaited. 
The results of trial with ovarian cancer are not 
encouraging.  
Shapiro et al. (2011) have developed small 
molecular inhibitors that reduce the interaction of 
ER and AR with DNA. One inhibitor that they have 
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studied in some detail is 8-
((benzylthio)methyl)theophylline (TPBM; 8-
benzylsulfanylmethyl-1,3-dimethyl-3,7- 
dihydropurine-2,6-dione) which decreases ER 
binding to ERE responsive genes. The structurally 
related ER inhibitor, p-fluoro-4-(1,2,3,6-tetrahydro-
1,3-dimethyl-2-oxo-6- thionpurin-8-
ylthio)butyrophenone (TPSF) was markedly more 
effective It was around 15-fold more potent than the 
parent compound. It would be interesting to see the 
phenotypic outcome of combination of these 
inhibitors with PR inhibitors. This research group 
has studied the PR inhibitor 6-Thio-8-(2-
ethylbutyl)thiotheophylline. This is novel in the 
sense that it binds outside the PR ligand-binding 
pocket (Aninye et al. 2012). Largely. such studies 
have not strayed beyond in vitro tests.  
Over the past few years several new progestins have 
surfaced, mainly for use in HRT. They may have 
protective effect by opposing cell proliferation 
induced by oestrogens. Indeed, it has been claimed 
that some progestins may prevent certain forms of 
cancer. 
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